## Xiao Chu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1417927/publications.pdf

Version: 2024-02-01

1478505 1372567 12 113 6 10 citations h-index g-index papers 12 12 12 167 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 107, 62-71.	0.8	25
2	Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2021, 111, 804-815.	0.8	22
3	Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors. Lung Cancer, 2020, 150, 178-185.	2.0	18
4	Deregulation of decorin and FHL1 are associated with esophageal squamous cell carcinoma progression and poor prognosis. International Journal of Clinical and Experimental Medicine, 2015, 8, 20965-70.	1.3	10
5	Recommendation for the definition of postoperative radiotherapy target volume based on a pooled analysis of patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma. Radiation Oncology, 2018, 13, 255.	2.7	9
6	Safety of early discharge with a chest tube after pulmonary segmentectomy. European Journal of Cardio-thoracic Surgery, 2020, 58, 613-618.	1.4	8
7	Learning curve for two-port video-assisted thoracoscopic surgery lung segmentectomy. Interactive Cardiovascular and Thoracic Surgery, 2022, 34, 402-407.	1.1	7
8	Expression of Hypoxia-inducible Factor Prolyl Hydroxylase 3 HIFPH3 in Human Non-small Cell Lung Cancer (NSCLC) and Its Correlation with Prognosis. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5819-5823.	1,2	5
9	A Case of Small Cell Lung Cancer Transformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib. Journal of Thoracic Oncology, 2018, 13, e211-e214.	1.1	4
10	Prolyl hydroxylase 3 involvement in lung cancer progression under hypoxic conditions: association with hypoxia-inducible factor- $\hat{11}$ and pyruvate kinase M2. Journal of Thoracic Disease, 2019, 11, 3941-3950.	1.4	4
11	Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons. British Journal of Radiology, 2022, 95, .	2.2	1
12	An N <sup>6</sup> -methyladenosine and target genes-based study on subtypes and prognosis of lung adenocarcinoma. Mathematical Biosciences and Engineering, 2022, 19, 253-270.	1.9	0